Search

Your search keyword '"Robinson, Giles W"' showing total 120 results

Search Constraints

Start Over You searched for: Author "Robinson, Giles W" Remove constraint Author: "Robinson, Giles W" Database Unpaywall Remove constraint Database: Unpaywall
120 results on '"Robinson, Giles W"'

Search Results

2. Cerebellar Mutism Syndrome and Dentato-Thalamo-Cortical Tract Disruption in Diffusion Tractography Following Surgery for Medulloblastoma

5. 6 Feasibility and Perceived Benefit of an Interdisciplinary Rehabilitation Approach within a Tertiary Pediatric Hematology/Oncology Setting

6. PATH-09. THE IMPACT OF MISMATCH REPAIR DEFICIENCY ON GLIOMAS IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS; A MULTI-CENTRIC, COLLABORATIVE STUDY LED BY THE IRRDC AND GLIOMA TASKFORCE

9. High-grade glioma in infants and young children is histologically, molecularly, and clinically diverse: Results from the SJYC07 trial and institutional experience

11. Data from Combination of Ribociclib and Gemcitabine for the Treatment of Medulloblastoma

12. Supplementary Data from Combination of Ribociclib and Gemcitabine for the Treatment of Medulloblastoma

13. Data from Combination of Ribociclib and Gemcitabine for the Treatment of Medulloblastoma

14. Supplementary Figure from Combination of Ribociclib and Gemcitabine for the Treatment of Medulloblastoma

15. Supplementary Figure from Combination of Ribociclib and Gemcitabine for the Treatment of Medulloblastoma

16. Supplementary Data from Combination of Ribociclib and Gemcitabine for the Treatment of Medulloblastoma

17. A sellar presentation of a WNT-activated embryonal tumor: further evidence of an ectopic medulloblastoma

18. Pub fees email yes from A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors

19. Pub fees email yes from A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors

20. Supplementary Figures from Relevance of Molecular Groups in Children with Newly Diagnosed Atypical Teratoid Rhabdoid Tumor: Results from Prospective St. Jude Multi-institutional Trials

21. Supplementary Figures from Relevance of Molecular Groups in Children with Newly Diagnosed Atypical Teratoid Rhabdoid Tumor: Results from Prospective St. Jude Multi-institutional Trials

22. Unified rhombic lip origins of group 3 and group 4 medulloblastoma

23. Molecular classification and outcome of children with rare CNS embryonal tumors: results from St. Jude Children’s Research Hospital including the multi-center SJYC07 and SJMB03 clinical trials

24. Combination of Ribociclib and Gemcitabine for the Treatment of Medulloblastoma

25. Phase II study of alisertib as a single agent for treating recurrent or progressive atypical teratoid/rhabdoid tumor

26. LGG-22. SJ901: Phase I/II evaluation of single agent mirdametinib (PD-0325901), a brain-penetrant MEK1/2 inhibitor, for the treatment of children, adolescents, and young adults with low-grade glioma (LGG)

28. Primary cilia control translation and the cell cycle in medulloblastoma

30. ATRT-22. Outcomes for children with recurrent atypical teratoid rhabdoid tumor: A single institution study with updated molecular and germline analysis

31. MEDB-69. Clinical and molecular meta-analysis of three major medulloblastoma clinical trials (ACNS0331, SJMB03, ACNS0332) uncovers novel strategies to improve risk-stratified therapy

32. Reducing Wait Time in a High-volume Pediatric Neuro-oncology Clinic by Optimizing Process Flow: A Quality Improvement Project

33. Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG)

36. Revised clinical and molecular risk strata define the incidence and pattern of failure in medulloblastoma following risk-adapted radiotherapy and dose-intensive chemotherapy: results from a phase III multi-institutional study

37. Serial assessment of measurable residual disease in medulloblastoma liquid biopsies

38. [11C]-Methionine PET for Identification of Pediatric High-Grade Glioma Recurrence

39. Lorlatinib in a Child with ALK-Fusion–Positive High-Grade Glioma

41. Patient-derived models recapitulate heterogeneity of molecular signatures and drug response in pediatric high-grade glioma

42. Clinical features, neurologic recovery, and risk factors of postoperative posterior fossa syndrome and delayed recovery: a prospective study

43. Relevance of Molecular Groups in Children with Newly Diagnosed Atypical Teratoid Rhabdoid Tumor: Results from Prospective St. Jude Multi-institutional Trials

44. Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03)

45. Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma

46. Clinical and molecular heterogeneity of pineal parenchymal tumors: a consensus study

47. Outcome and molecular analysis of young children with choroid plexus carcinoma treated with non-myeloablative therapy: results from the SJYC07 trial

48. Patient-Derived Orthotopic Xenografts and Cell Lines from Pediatric High-Grade Glioma Recapitulate the Heterogeneity of Histopathology, Molecular Signatures, and Drug Response

49. MBCL-21. GERMLINE ELONGATOR MUTATIONS IN SONIC HEDGEHOG MEDULLOBLASTOMA

50. MBRS-24. FUNCTIONAL CHARACTERIZATION OF IKBKAP/ELP1 AS A NOVEL SHH MEDULLOBLASTOMA PREDISPOSITION GENE

Catalog

Books, media, physical & digital resources